Clinical Trials
4 trialsNCT05522387 2026-02-27
An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
Inmune Bio, Inc.
Phase 2 Terminated
NCT02142959 2025-06-03
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
Biogen
Phase 2 Completed
NCT05321498 2023-09-28
Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation
Inmune Bio, Inc.
Phase 2 Withdrawn
NCT00537667 2009-11-26
The SPECTRA Study
Swedish Orphan Biovitrum
Phase 2 Terminated